Posted on September 24th, 2009 by
Among patients with previously treated, metastatic colorectal cancer, the addition of the targeted therapy Vectibix® (panitumumab) to chemotherapy delayed cancer progression. This benefit was only observed in patients whose tumors did not contain a mutation in the KRAS gene. These results were presented at a major European cancer conference.
Colorectal cancer remains the second leading cause of cancer-related death in the United States. Metastatic colorectal cancer refers to cancer that has spread from the colon to distant sites in the body.
Targeted therapies are anticancer drugs that interfere with specific pathways involved in cancer cell growth or survival. Some targeted therapies block growth signals from reaching cancer cells; others reduce the blood supply to cancer cells; and still others stimulate the immune system to recognize and attack the cancer cell. Depending on the specific “target,” targeted therapies may slow cancer cell growth or increase cancer cell death.
Vectibix inhibits cancer cell growth and survival by targeting a protein known as the epidermal growth factor receptor (EGFR). Vectibix has been approved for the treatment of EGFR-expressing, metastatic colorectal cancer that has progressed on or following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens. Vectibix appears to benefit only those patients whose cancers do not contain a mutation in a gene known as KRAS. KRAS mutations occur in an estimated 40-50% of metastatic colorectal cancers and can be identified by testing a sample of tumor tissue.
To evaluate the effectiveness of Vectibix in the second-line treatment of metastatic colorectal cancer, researchers conducted a Phase III clinical trial among 1,186 patients. Study participants were assigned to receive treatment with FOLFIRI chemotherapy alone or FOLFIRI plus Vectibix.
The results of this study suggest that the addition of the targeted therapy Vectibix to second-line chemotherapy improves progression-free survival among patients with metastatic colorectal cancer. The benefit only applies to patients whose tumors do not contain KRAS mutations.
Reference: Peeters M, Trice T, Hotko Y et al. Randomized phase 3 study of panitumumab with FOLFIRI vs FOLFIRI alone as second-line treatment (tx) in patients (pts) with metastatic colorectal cancer (mCRC). Presented at the Joint ECCO 15-34th ESMO Multidisciplinary Congress. Berlin, Germany, September 20-24, 2009. Abstract 14LBA.
Copyright © 2010 CancerConsultants Colon Cancer Information Center. All Rights Reserved.
You must be logged-in to the site to post a comment.